HealthcareServices

Global Cancer Gene Therapy Market Report 2026–2030: Data-Driven Growth Insights

February 20, 2026February 23, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the cancer gene therapy market from 2026–2035 with trusted insights from The Business Research Company

What is the expected shift in the Cancer Gene Therapy Market’s size between 2026 and 2030?

The cancer gene therapy market size has shown rapid expansion in recent years. It is projected to grow from $4.21 billion in 2025 to $4.9 billion in 2026, reflecting a compound annual growth rate (CAGR) of 16.4%. The growth observed in the past can be attributed to advancements in molecular oncology research, the expansion of clinical trials in gene therapy, increasing investment in biopharmaceutical R&D, regulatory approvals of early gene therapies, and improved vector manufacturing capabilities.

The cancer gene therapy market size is anticipated to experience swift expansion over the next few years, reaching $8.9 billion by 2030 with a compound annual growth rate (CAGR) of 16.1%. This projected growth during the forecast period is fueled by an increasing demand for personalized cancer treatments, rising investment in cell and gene therapy manufacturing, the expansion of next-generation viral vectors, a growing emphasis on combination oncology therapies, and the increasing adoption of precision oncology approaches. Significant trends during this period include the accelerated development of targeted gene therapy platforms, the rising adoption of CAR-T and TCR therapies, a heightened focus on viral vector optimization, the broader availability of personalized cancer gene treatments, and enhanced integration of biomarker-guided therapy selection.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27233&type=smp

Which Drivers Are Shaping Strategic Decisions In The Cancer Gene Therapy Market?

The rising occurrence of cancer is anticipated to drive the expansion of the cancer gene therapy market in the future. Cancer is defined as a condition marked by the uncontrolled proliferation of atypical cells, capable of invading and spreading throughout the body, originating in diverse tissues and organs, and categorized by its cell or tissue of origin. The number of cancer cases is escalating primarily due to increased life expectancy, given that the likelihood of developing cancer increases with advancing age. Cancer gene therapy addresses cancer by altering or substituting defective genes to halt the proliferation of cancer cells or to boost the immune system’s capacity to eliminate them. As an illustration, in August 2024, Macmillan Cancer Support, an organization located in the UK, stated that over 3 million individuals in the UK are currently living with cancer. This number is forecasted to climb to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. Consequently, the growing incidence of cancer is propelling the development of the cancer gene therapy market.

What Segment Categories Are Covered In The Cancer Gene Therapy Market?

The cancer gene therapy market covered in this report is segmented –

1) By Therapy: Gene Induced Immunotherapy, Oncolytic Virotherapy, Gene Transfer

2) By Indication: Large B-Cell Lymphoma, Multiple Myeloma, Acute Lymphoblastic Leukemia (ALL), Melanoma (lesions), Other Indications

3) By Vector Type: Lentivirus, RetroVirus And Gamma RetroVirus, Adeno-Associated Virus (AAV), Modified Herpes Simplex Virus, Adenovirus, Other Vector Types

4) By End-User: Hospitals, Research Institutes, Biopharma Companies, Cell Therapy Manufacturing Centers, Other End Users

Subsegments:

1) By Gene Induced Immunotherapy: CAR-T Cell Therapy, TCR (T-Cell Receptor) Therapy, Tumor-Infiltrating Lymphocyte (TIL) Therapy, Dendritic Cell-Based Gene Therapy, NK Cell Gene Therapy

2) By Oncolytic Virotherapy: Adenoviruses, Herpes Simplex Virus (HSV), Reovirus, Vaccinia Virus, Newcastle Disease Virus (NDV)

3) By Gene Transfer: Viral Gene Transfer, Non-Viral Gene Transfer

Which Innovation Trends Are Advancing Developments Within The Cancer Gene Therapy Market?

Leading companies active in the cancer gene therapy market are concentrating on developing advanced treatments, such as CAR-T cell therapy, to enhance therapeutic precision, improve patient outcomes, and target cancer cells more effectively while minimizing harm to healthy tissues. CAR-T therapy is a sophisticated immunotherapy where a patient’s immune cells are genetically modified with special receptors to better detect and eliminate cancer cells. For instance, in April 2024, ImmunoACT, an India-based biotechnology company, launched NexCAR19 (actalycabtagene autoleucel), the nation’s first domestically developed CAR-T cell therapy for cancer. Specifically designed to treat B-cell lymphomas and leukemias, NexCAR19 operates by reprogramming a patient’s own T cells to identify and destroy cancer cells. Built on advanced chimeric antigen receptor (CAR) technology, the therapy is locally produced, making it more affordable and accessible than imported options. This launch represents a significant milestone for India’s entry into the global cancer gene therapy domain, underscoring notable progress in domestic innovation and personalized cancer care.

Which Key Players Are Driving Competition In The Cancer Gene Therapy Market?

Major companies operating in the cancer gene therapy market are Bristol Myers Company, Novartis AG, GSK plc., Gilead Sciences Inc., Amgen Inc., Orchard Therapeutics Plc, AGC Biologics, Adaptimmune Limited, Sibiono, Elevate Bio Inc., Bluebird Bio Inc., Uniqure N.V., Shanghai Sunway Biotech Co. Ltd., Anges Inc., Gensight Biologics, Genelux Corporation, Cellectis, Abeona Therapeutics Inc., Kite Pharma Inc., Janssen Biotech Inc., Mustang Bio Inc., Intellia Therapeutics Inc., CRISPR Therapeutics AG, Caribou Biosciences Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/cancer-gene-therapy-global-market-report

Which Region Is Projected To Lead The Cancer Gene Therapy Market During The Forecast Period?

North America was the largest region in the cancer gene therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer gene therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Cancer Gene Therapy Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=27233&type=smp

Browse Through More Reports Similar to the Global Cancer Gene Therapy Market 2026, By The Business Research Company

Farm Equipment Rental Market Report 2026

https://www.thebusinessresearchcompany.com/report/farm-equipment-rental-global-market-report

Commercial Fan And Air Purification Equipment Market 2026

https://www.thebusinessresearchcompany.com/report/commercial-fan-and-air-purification-equipment-market

Commercial Fan And Air Purification Equipment Market 2026

https://www.thebusinessresearchcompany.com/report/commercial-fan-and-air-purification-equipment-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795